908116-30-3

Upstream product

• 126-81-8 dimedone 
• 1755-15-3 2-acetyldimedone 
• 1292848-43-1 4-hydrazino-2-(4-hydroxy-cyclohexylamino)-benzonitrile 
• 917003-39-5 4-Fluoro-2-(4-hydroxy-cyclohexylamino)-benzonitrile 
• 917003-26-0 C₂₃H₂₈N₄O₂ 

Downstream Products

• 1265225-74-8 BJ-B₁₁ 
• 1268603-11-7 2-(4-(3-acetylcarnitineacyloxy)cyclohexylamino)-4-(1-(3,6,6-trimethyl-4-oxy-4,5,6,7-tetrahydroindazole))benzamide 

Relevant academic research and scientific papers

Synthesis and in vitro anti-HSV-1 activity of a novel Hsp90 inhibitor BJ-B11

In this study, a novel Hsp90 inhibitor BJ-B11, was synthesized and evaluated for in vitro antiviral activity against several viruses. Possible anti-HSV-1 mechanisms were also investigated. BJ-B11 displayed no antiviral activity against coxsackievirus B3 (CVB3), human respiratory syncytial virus (RSV) and influenza virus (H1N1), but exhibited potent anti-HSV-1 and HSV-2 activity with EC50 values of 0.42 ± 0.18 μM and 0.60 ± 0.21 μM, respectively. Additionally, the inhibitory effects of BJ-B11 against HSV-1 were likely to be introduced at early stage of infection. Our results indicate that BJ-B11 with alternative mechanisms of action is potent as an anti-HSV clinical trial candidate.